Comparative Benchmarking
In the context of the broader market, PHAR competes directly with industry leaders such as AKTS and PCRX. With a market capitalization of $1.15B, it holds a leading position in the sector. When comparing efficiency, PHAR's gross margin of N/A stands against AKTS's 47.66% and PCRX's 72.93%. Such benchmarking helps identify whether Pharming Group NV is trading at a premium or discount relative to its financial performance.
